StreetInsider.com News Articles

Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 08:30:00 -0400

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and

Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 22 Oct 2026 08:30:00 -0400

Vericel Corporation (VCEL) PT Lowered to $52 at Truist Securities

Wed, 14 Oct 2026 07:00:37 -0400

Truist Securities analyst Richard Newitter lowered the price target on Vericel Corporation (NASDAQ: VCEL) to $52.00 (from $58.00) while maintaining a Buy rating.

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.

Tue, 06 Oct 2026 09:06:00 -0400

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include:

MediWound gets $3.3M more from U.S. government for NexoBrid program

Tue, 22 Sep 2026 07:04:16 -0400

MediWound Ltd. (NASDAQ: MDWD) has received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formulation of its NexoBrid® product, according to a company statement.
The supplemental award brings the total program budget to $21.8 million. The funding is non-dilutive and is intended to support development through the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
NexoBrid is an FDA-approved biologic used for the enzymatic removal of eschar in thermal burns. The room-temperature-stable formulation is being developed as a non-surgical debridement option for battlefield burn care, where cold-chain storage and

MediWound gets $3.3M more from U.S. government for NexoBrid program

Tue, 22 Sep 2026 07:04:16 -0400

MediWound Ltd. (NASDAQ: MDWD) has received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formulation of its NexoBrid® product, according to a company statement.
The supplemental award brings the total program budget to $21.8 million. The funding is non-dilutive and is intended to support development through the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration.
NexoBrid is an FDA-approved biologic used for the enzymatic removal of eschar in thermal burns. The room-temperature-stable formulation is being developed as a non-surgical debridement option for battlefield burn care, where cold-chain storage and

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid^® as a non-surgical debridement solution for battlefield

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid^® as a non-surgical debridement solution for battlefield

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid^® as a non-surgical debridement solution for battlefield

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®

Tue, 22 Sep 2026 07:00:00 -0400

MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid^®

Award raises the total program budget to $21.8 million and supports development through Investigational New Drug (IND) submission for battlefield burn care

YAVNE, Israel, September 22, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of War (DoW) has awarded the Company an additional $3.3 million in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid^® as a non-surgical debridement solution for battlefield

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

Tue, 08 Sep 2026 08:30:00 -0400

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15^th, 2026.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

Tue, 08 Sep 2026 08:30:00 -0400

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15^th, 2026.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology

Form 4 Vericel Corp For: Aug 12 Filed by: MCLAUGHLIN KEVIN F

Fri, 14 Aug 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260814/26930308.html

Form 4 Vericel Corp For: Aug 12 Filed by: MCLAUGHLIN KEVIN F

Fri, 14 Aug 2026 16:10:00 -0400
si-local-file:///var/storage/secattach/20260814/26930308.html

Form SCHEDULE 13G/A Vericel Corp Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400
si-local-file:///var/storage/secattach/20260813/26917406.html

Form SCHEDULE 13G/A Vericel Corp Filed by: Soleus Capital Master Fund, L.P.

Thu, 13 Aug 2026 09:00:00 -0400
si-local-file:///var/storage/secattach/20260813/26917406.html